Inhibition of LPS-induced neutrophil recruitment in the lungs correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933 Source: Eur Respir J 2004; 24: Suppl. 48, 218s Year: 2004
CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin Source: ERJ Open Res, 6 (4) 00583-2020; 10.1183/23120541.00583-2020 Year: 2020
Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
The selective CXCR2 receptor antagonist SB-656933 inhibits CXCL1-induced neutrophil CD11b expression in human whole blood Source: Eur Respir J 2004; 24: Suppl. 48, 218s Year: 2004
Roflumilast potently inhibits CXCL1 mediated neutrophil migration in COPD patients Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011
Chemokine release by neutrophils in COPD Source: Annual Congress 2011 - Macrophages and neutrophils in chronic lung disease Year: 2011
Neutrophils and neutrophil chemokine receptor (CXCR1 and 2) gene expression in severe exacerbations of COPD and asthma Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001
Elevated CCL2 responses in COPD and attenuation by selective chemokine receptor antagonists Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects Source: Eur Respir J 2010; 35: 564-570 Year: 2010
Endobronchial biopsy neutrophilia, IL-8, ENA-78 and neutrophil chemokine receptor (CXCR1 & CXCR2) gene expression in severe exacerbations of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 377s Year: 2002
Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils Source: Eur Respir J, 51 (4) 1700970; 10.1183/13993003.00970-2017 Year: 2018
Endobronchial biopsy neutrophilia, IL-8, ENA-78 and neutrophil chemokine receptor (CXCR1 and CXCR2) gene expression in severe exacerbations of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 588s Year: 2003
Inhaled CCR1 antagonist AZD4818 reduces leucocyte influx in the rat lipopolysaccharide (LPS) lung inflammation model Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Effects of N-acetylcysteine and salbutamol on neutrophil migration and release of interleukin-8 and elastase by neutrophils in vitro Source: Eur Respir J 2004; 24: Suppl. 48, 579s Year: 2004
SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects Source: Annual Congress 2007 - New drugs for COPD Year: 2007
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD Source: Eur Respir J 2016; 47: 1093-1102 Year: 2016
Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD Source: Eur Respir J, 52 (4) 1801020; 10.1183/13993003.01020-2018 Year: 2018
Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004